Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells.

Mitsuuchi Y, Benetatos CA, Deng Y, Haimowitz T, Beck SC, Arnone MR, Kapoor GS, Seipel ME, Chunduru SK, McKinlay MA, Begley CG, Condon SM.

Cell Death Discov. 2017 Jan 16;3:16046. doi: 10.1038/cddiscovery.2016.46. eCollection 2017.

2.

Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways.

Tanzer MC, Khan N, Rickard JA, Etemadi N, Lalaoui N, Spall SK, Hildebrand JM, Segal D, Miasari M, Chau D, Wong WL, McKinlay M, Chunduru SK, Benetatos CA, Condon SM, Vince JE, Herold MJ, Silke J.

Cell Death Differ. 2017 Mar;24(3):481-491. doi: 10.1038/cdd.2016.147. Epub 2017 Jan 20.

3.

RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL.

Lawlor KE, Khan N, Mildenhall A, Gerlic M, Croker BA, D'Cruz AA, Hall C, Kaur Spall S, Anderton H, Masters SL, Rashidi M, Wicks IP, Alexander WS, Mitsuuchi Y, Benetatos CA, Condon SM, Wong WW, Silke J, Vaux DL, Vince JE.

Nat Commun. 2015 Feb 18;6:6282. doi: 10.1038/ncomms7282.

4.

Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.

Condon SM, Mitsuuchi Y, Deng Y, LaPorte MG, Rippin SR, Haimowitz T, Alexander MD, Kumar PT, Hendi MS, Lee YH, Benetatos CA, Yu G, Kapoor GS, Neiman E, Seipel ME, Burns JM, Graham MA, McKinlay MA, Li X, Wang J, Shi Y, Feltham R, Bettjeman B, Cumming MH, Vince JE, Khan N, Silke J, Day CL, Chunduru SK.

J Med Chem. 2014 May 8;57(9):3666-77. doi: 10.1021/jm500176w. Epub 2014 Apr 15.

PMID:
24684347
5.

Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.

Benetatos CA, Mitsuuchi Y, Burns JM, Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, Laporte MG, Rippin SR, Deng Y, Hendi MS, Tirunahari PK, Lee YH, Haimowitz T, Alexander MD, Graham MA, Weng D, Shi Y, McKinlay MA, Chunduru SK.

Mol Cancer Ther. 2014 Apr;13(4):867-79. doi: 10.1158/1535-7163.MCT-13-0798. Epub 2014 Feb 21. Erratum in: Mol Cancer Ther. 2014 Sep;13(9):2246-7. Dosage error in article text.

6.

The discovery and structure-activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase.

Jackson RW, LaPorte MG, Herbertz T, Draper TL, Gaboury JA, Rippin SR, Patel R, Chunduru SK, Benetatos CA, Young DC, Burns CJ, Condon SM.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3227-31. doi: 10.1016/j.bmcl.2011.04.052. Epub 2011 Apr 21.

PMID:
21550237
7.

The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase.

LaPorte MG, Draper TL, Miller LE, Blackledge CW, Leister LK, Amparo E, Hussey AR, Young DC, Chunduru SK, Benetatos CA, Rhodes G, Gopalsamy A, Herbertz T, Burns CJ, Condon SM.

Bioorg Med Chem Lett. 2010 May 1;20(9):2968-73. doi: 10.1016/j.bmcl.2010.03.002. Epub 2010 Mar 6.

PMID:
20347591
8.

The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity.

Laporte MG, Jackson RW, Draper TL, Gaboury JA, Galie K, Herbertz T, Hussey AR, Rippin SR, Benetatos CA, Chunduru SK, Christensen JS, Coburn GA, Rizzo CJ, Rhodes G, O'Connell J, Howe AY, Mansour TS, Collett MS, Pevear DC, Young DC, Gao T, Tyrrell DL, Kneteman NM, Burns CJ, Condon SM.

ChemMedChem. 2008 Oct;3(10):1508-15. doi: 10.1002/cmdc.200800168. No abstract available.

PMID:
18729128
9.

TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.

Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, McKinlay M, Benetatos CA, Condon SM, Chunduru SK, Yeoh G, Brink R, Vaux DL, Silke J.

J Cell Biol. 2008 Jul 14;182(1):171-84. doi: 10.1083/jcb.200801010. Epub 2008 Jul 7.

10.

IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.

Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J.

Cell. 2007 Nov 16;131(4):682-93.

11.

Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase.

Howe AY, Bloom J, Baldick CJ, Benetatos CA, Cheng H, Christensen JS, Chunduru SK, Coburn GA, Feld B, Gopalsamy A, Gorczyca WP, Herrmann S, Johann S, Jiang X, Kimberland ML, Krisnamurthy G, Olson M, Orlowski M, Swanberg S, Thompson I, Thorn M, Del Vecchio A, Young DC, van Zeijl M, Ellingboe JW, Upeslacis J, Collett M, Mansour TS, O'Connell JF.

Antimicrob Agents Chemother. 2004 Dec;48(12):4813-21.

12.

Mechanism of action of a pestivirus antiviral compound.

Baginski SG, Pevear DC, Seipel M, Sun SC, Benetatos CA, Chunduru SK, Rice CM, Collett MS.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7981-6.

13.

Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells.

Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR.

Br J Cancer. 1998 Feb;77(4):562-6.

14.
15.

Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy.

Ranganathan S, Salazar H, Benetatos CA, Hudes GR.

Prostate. 1997 Mar 1;30(4):263-8.

PMID:
9111604
16.

Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.

Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR.

Cancer Res. 1996 Jun 1;56(11):2584-9.

Supplemental Content

Loading ...
Support Center